LiverMultiScan® detected earlier stages of treatable disease in patients with autoimmune hepatitis to allow tailored treatment
- March 21, 2022
OXFORD, England – March 21, 2022. A first-of-its-kind study published in eClinicalMedicine - The Lancet, found that LiverMultiScan cT1 (an MRI-derived non-invasive tissue biomarker), improved autoimmune hepatitis (AIH) management by identifying patients in biochemical remission as well as patients in deep remission, with undetected, active sub-clinical disease at a high risk of disease relapse.
AIH is a chronic, life-long condition, characterized by liver inflammation. Patients with AIH often experience recurring periods of subdued disease activity, experiencing few or no symptoms, followed by disease flares and worsening liver health – making disease management exceptionally challenging for clinicians. Clinical monitoring of AIH currently relies on blood biomarkers, which are non-specific and cannot detect small, but clinically relevant, changes in disease activity. Therefore, there is an urgent unmet need to adopt improved non-invasive techniques that can accurately stage and monitor disease, allowing for individualized patient management in AIH.
This new study by Kings College Hospital and Oxford University Hospitals demonstrated that cT1 measurements obtained with Perspectum’s LiverMultiScan performed better than blood biomarkers and FibroScan® in identifying those patients likely to experience disease progression, despite being in biochemical remission. Furthermore, this additional information had a positive impact on the clinicians’ intended management plan. As the majority of patients with AIH require life-long monitoring, LiverMultiScan can help clinicians identify those with active sub-clinical disease, despite having normal blood markers, to provide tailored clinical treatment.
"I'd like people to know that LiverMultiScan is a game-changer for clinicians and healthcare systems and a life changer for patients", said Pamela Tollett, a patient living with AIH for over two decades. "Unfortunately, the current method of monitoring AIH, using blood markers, is not an accurate reflection of the extent of inflammation – blood work can be totally normal whilst the disease is bubbling away, causing damage. Regular LiverMultiScan monitoring will mean swifter and more accurate clinical responses, enabling medication to be used at optimal levels and duration."
“LiverMultiScan positively impacted physicians’ decision making with clinicians reporting high confidence in its utility in clinical management of patients with autoimmune hepatitis. This first-of-its-kind, real-world study by Kings College Hospital and Oxford University Hospitals, demonstrates that Perspectum’s quantitative MRI method identified active disease and predicted risk of disease relapse,” stated Matt Kelly, Chief Innovation Officer.
Read the full paper here.
Perspectum, a global medical technology company with offices in the U.K., the U.S., Portugal and Singapore, delivers leading digital technologies that help clinicians provide better care for patients with chronic metabolic diseases, multi-organ pathology and cancer. With a strong focus on precision medicine using advanced imaging and genetics, our vision is to empower patients and clinicians through quantitative assessments of health enabling early detection, diagnosis, and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers and technologists, Perspectum offers a way to manage complex health problems at scale.
For Further Information:
VP Corporate Affairs